Skip to main content
. 2022 Mar;32(2):1064–1072. doi: 10.1177/11206721211010613

Table 4.

Comparison of clinical and demographical characteristics of patients according to presence of complications at first post-COVID-19 visit.

Complication at first post-COVID-19 visit p
Yes No
Gender, n(%)
 Male 10 (50.0) 52 (43.3) 0.578a
 Female 10 (50.0) 68 (56.7)
Eye laterality, n(%)
 Right 11 (55.0) 69 (57.5) 0.834a
 Left 9 (45.0) 51 (42.5)
Fellow eye, n(%)
 Drusen 14 (70.0) 75 (62.5) 0.883b
 Disciform scar 4 (20.0) 28 (23.3)
 Macular NV 2 (10.0) 17 (14.2)
Initial nAMD type, n(%)
 Type-1 15(75) 84(70) 0.858b
 Type-2 4(20) 23(19,2)
 Mixt 1(5) 13(10,8)
Initial treatment, n(%)
 Aflibercept 9(45) 79(65,8) 0.002 b
 Ranibizumab 1(5) 24(20)
 Bevacizumab 10(50) 17(14,2)
Intravitreal injection at last 6 months, n(%)
 Yes 20(100) 84(70) 0.004 a
 No 0(0) 36(30)
Three intravitreal loading injections, n(%)
 Yes 10(50) 115(95,8) 0.001 c
 No 10(50) 5(4,2)
Age (years), mean ± SD (min-max) 68.2 ± 8.7 (55–85) 72.7 ± 8.7 (55–92) 0.064d
Follow-up duration (months), mean ± SD (min-max) 11.9 ± 14.8 (3–60) 26.3 ± 14.5 (5–83) 0.001 e
Baseline BCVA (ETDRS letters), mean ± SD (min-max) 38.2 ± 23.1 (5–70) 42.8 ± 25.7 (5–83) 0.493e
BCVA at last pre-COVID-19 visit (ETDRS letters), mean ± SD (min-max) 51.1 ± 22.5 (5–83) 50.1 ± 23.9 (5–85) 0.900e
Baseline CST (µm), mean ± SD (min-max) 345.5 ± 30.4 (289–404) 345.1 ± 34.4 (285–466) 0.956d
CST at last pre-COVID-19 visit (µm), mean ± SD (min-max) 294.3 ± 25.8 (246–328) 281.9 ± 26.1 (218–345) 0.051d
Total number of control visits, mean ± SD (min-max) 8.7 ± 10.3 (2–40) 17.4 ± 9.2 (2–57) 0.001 e
Total number of intravitreal injections, mean ± SD (min-max) 5.5 ± 4.9 (2–20) 9.0 ± 4.9 (2–27) 0.001 e
Total number of intravitreal injections at last 6 months, mean ± SD (min-max) 2.8 ± 1.5 (1–6) 1.6 ± 1.2 (0–5) 0.007 e
Pre-COVID-19 injection interval (weeks), mean ± SD (min-max) 7.5 ± 2.8 (4–13) 12.3 ± 5.2 (5–28) 0.001 e
Duration between last pre-COVID-19 and first post-COVID-19 intravitreal injection (weeks), mean ± SD (min-max) 25.2 ± 5.9 (12–32) 30.1 ± 14.9 (12–64) 0.769e
Pre-COVID-19 visit interval (weeks), mean ± SD (min-max) 5.1 ± 1.4 (4–8) 6.1 ± 1.6 (4–12) 0.005 e
Duration between last pre-COVID-19 and first post-COVID-19 follow-up visit (weeks), mean ± SD (min-max) 23.8 ± 6.9 (12–32) 18.9 ± 4.9 (12–32) 0.001 e

n = Number of Patients, SD = Standard Deviation, BCVA = Best Corrected Visual Acuity, CST = Central subfoveal thickness, NV = Neovascularisation.

a

Pearson Chi-Square Test, bFisher Freeman Halton Test, cFisher’s Exact Test, dStudent-t Test, eMann Whitney U Test.

p<0.05 accepted as statistically significant. (Statistically significant values denoted in bold)